Wasatch Advisors LP Sells 105,717 Shares of Artivion, Inc. (NYSE:AORT)

Wasatch Advisors LP trimmed its holdings in shares of Artivion, Inc. (NYSE:AORT) by 11.5% in the 3rd quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The firm owned 815,832 shares of the company’s stock after selling 105,717 shares during the quarter. Wasatch Advisors LP owned approximately 1.95% of Artivion worth $21,717,000 at the end of the most recent quarter.

Other large investors also recently added to or reduced their stakes in the company. Perceptive Advisors LLC boosted its position in shares of Artivion by 4.7% in the second quarter. Perceptive Advisors LLC now owns 2,793,703 shares of the company’s stock worth $71,658,000 after purchasing an additional 124,725 shares during the period. Vanguard Group Inc. boosted its position in shares of Artivion by 1.3% in the first quarter. Vanguard Group Inc. now owns 2,664,855 shares of the company’s stock worth $56,388,000 after purchasing an additional 33,982 shares during the period. First Eagle Investment Management LLC boosted its position in shares of Artivion by 4.9% in the second quarter. First Eagle Investment Management LLC now owns 598,148 shares of the company’s stock worth $15,342,000 after purchasing an additional 27,906 shares during the period. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC boosted its position in shares of Artivion by 58.4% in the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 340,887 shares of the company’s stock worth $9,074,000 after purchasing an additional 125,668 shares during the period. Finally, Bank of New York Mellon Corp boosted its position in shares of Artivion by 0.7% in the second quarter. Bank of New York Mellon Corp now owns 301,992 shares of the company’s stock worth $7,746,000 after purchasing an additional 2,018 shares during the period. 86.37% of the stock is currently owned by institutional investors.

Insider Activity at Artivion

In other news, CAO Amy Horton sold 12,430 shares of the stock in a transaction on Tuesday, October 1st. The shares were sold at an average price of $26.18, for a total value of $325,417.40. Following the sale, the chief accounting officer now owns 139,989 shares of the company’s stock, valued at approximately $3,664,912.02. This represents a 8.16 % decrease in their ownership of the stock. The sale was disclosed in a legal filing with the SEC, which can be accessed through this link. 8.10% of the stock is owned by insiders.

Analyst Ratings Changes

A number of equities analysts recently weighed in on AORT shares. Oppenheimer upped their target price on shares of Artivion from $30.00 to $32.00 and gave the stock an “outperform” rating in a research report on Friday, November 8th. Needham & Company LLC restated a “buy” rating and set a $30.00 target price on shares of Artivion in a research report on Friday, September 27th. JMP Securities started coverage on shares of Artivion in a research report on Wednesday, October 23rd. They set an “outperform” rating and a $33.00 target price for the company. Finally, Stifel Nicolaus upped their target price on shares of Artivion from $28.00 to $30.00 and gave the stock a “buy” rating in a research report on Friday, September 13th. Five research analysts have rated the stock with a buy rating, According to data from MarketBeat, the company currently has a consensus rating of “Buy” and an average target price of $31.00.

Artivion Price Performance

Artivion stock opened at $29.52 on Friday. The company has a market cap of $1.24 billion, a price-to-earnings ratio of -1,476.00 and a beta of 1.75. The firm’s fifty day moving average is $27.00 and its 200 day moving average is $25.81. The company has a quick ratio of 1.33, a current ratio of 1.88 and a debt-to-equity ratio of 0.71. Artivion, Inc. has a 52-week low of $16.48 and a 52-week high of $30.00.

Artivion Company Profile

Artivion, Inc manufactures, processes, and distributes medical devices and implantable human tissues worldwide. The company provides BioGlue, a polymer consisting of bovine blood protein and an agent for cross-linking proteins for cardiac, vascular, neurologic, and pulmonary procedures; cardiac preservation services; PhotoFix, a bovine pericardial patch; and aortic arch stent grafts including E-vita Open Plus and E-vita Open Neo.